TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03704688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib 0.5 mg
Description: 0.5mg PO q daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib 1 MG
Description: 1.0 mg PO q daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib 1.5 MG
Description: 1.5mg PO q daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib 2 mg
Description: 2 mg PO q daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib 2 mg
Description: 2 mg PO q daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib 2 mg
Description: 2 mg PO q daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib 15 MG
Description: 15mg PO q daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib 15 MG
Description: 15mg PO q daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib 15 MG
Description: 15mg PO q daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib 15 MG
Description: 15mg PO q daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib 15 MG
Description: 15mg PO q daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib 30 MG
Description: 30mg PO q daily
Study: NCT02826096

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biofeedback therapy
Description: The brief version of biofeedback therapy is conducted by psychologists following the structure way. Biofeedback therapy is six session treatment once a week.
Study: NCT04493177

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational intervention
Description: Monthly 45-minute sessions will be held, including dietary, and physical activity modification, early stimulation, exclusive breastfeeding for 6 months and the proper introduction of foods, and other support for the mother. The sessions will be supported by personalized contact by WhatsApp and programmed telephone calls, in addition to conventional treatment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational intervention
Description: Monthly 45-minute sessions will be held, including dietary, and physical activity modification, early stimulation, exclusive breastfeeding for 6 months and the proper introduction of foods, and other support for the mother. The sessions will be supported by personalized contact by WhatsApp and programmed telephone calls, in addition to conventional treatment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional treatment Guia de Practica Clinica IMSS-029-08
Description: Conventional treatment includes some early stimulation, monthly visits for height/weight measurement of the offspring.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional treatment Guia de Practica Clinica IMSS-029-08
Description: Conventional treatment includes some early stimulation, monthly visits for height/weight measurement of the offspring.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment Guia de Practica Clinica IMSS-029-08
Description: Conventional treatment includes some early stimulation, monthly visits for height/weight measurement of the offspring.
Study: NCT04335864

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic salpingectomy
Description: 39 patients with hydrosalpinx will have laparoscopic salpingectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hystroscopic proximal tubal occlusion
Description: 39 patients with hydrosalpinx will have hysteroscopic proximal tubal occlusion
Study: NCT04419168

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cCBT
Description: A digital, internet-delivered, evidence-based chatbot programmed to deliver content for both cCBT.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: m-Education
Description: A digital, internet-delivered, evidence-based chatbot programmed to deliver content for both m-Education.
Study: NCT02712853

Intervention type: OTHER
Intervention: Saliva collection
Description: Collection of saliva via swab for miRNA processing

Intervention type: OTHER
Intervention: Saliva collection
Description: Collection of saliva via swab for miRNA processing

Intervention type: OTHER
Intervention: Vineland Adaptive Behavior Scale-II Assessment

Intervention type: OTHER
Intervention: Vineland Adaptive Behavior Scale-II Assessment
Study: NCT01426126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genexol PM
Description: Genexol-PM at a dose of 240 mg/㎡ was diluted in 500 ml of 5% dextrose solution and infused i.v. for 3 hours on day 1. Specialized i.v. infusion sets or in-line filter was not required for the administration. The dose of Genexol-PM was escalated to 300 mg/㎡ from the second cycle when pre-specified criteria were fulfilled (nadir ANC ≥ 1,000/ mm3, nadir platelet count ≥ 100,000/ mm3, and no grade 2 or worse non-hematologic toxicities with the exception of alopecia)
Study: NCT03268863

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Google Cardboard virtual reality headset

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Cold Pressor
Description: A cold ice water bath for use in pain/discomfort simulation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold Pressor
Description: A cold ice water bath for use in pain/discomfort simulation
Study: NCT01768273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA-824
Study: NCT02911116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: Subcutaneous Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: Subcutaneous Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: Intravenous Infusion
Study: NCT02859012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: Dosing schedule: 5mg twice per day orally (4 weeks is considered as 1 cycle)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Observation
Description: this group is observational ones.
Study: NCT01482221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6765 iv
Description: 50 mg (AZD6765 Solution for Infusion, 0.5 mg/mL) by iv infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6765 iv
Description: 100 mg (AZD6765 Solution for Infusion, 1.0 mg/mL) by iv infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9 sodium chloride \[normal saline\] solution for injection by iv infusion
Study: NCT01549509

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVADV014-00-VP Vaccine
Description: All participants will receive one injection in their upper arm of 1 x 10\^10 particle units (PU)/mL of VRC-HIVADV014-00-VP at study entry.
Study: NCT02115152

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluorouracil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Study: NCT01159847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin
Description: sitagliptin tablet,100 mg p.o. qd,2 year

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Study: NCT03436719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral antibiotic
Description: Metronidazole - 500 mg and Erythromycin - 500 mg per os \*3 times at 5 p.m.; 8 p.m., 11 p.m. in a day before surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous antibiotic
Description: Cefoperazone - 1000 mg intravenously for 30-90 minutes before surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous antibiotic
Description: Cefoperazone - 1000 mg intravenously for 30-90 minutes before surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical Bowel Preparation
Description: Beginning of MBP at 4 p.m. in a day before surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mechanical Bowel Preparation
Description: Beginning of MBP at 4 p.m. in a day before surgery
Study: NCT02768155

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Amniotic Fluid 4.0ml dose
Description: Injection of Amniotic Fluid

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Amniotic Fluid 2.0ml dose
Description: Injection of Amniotic Fluid

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control
Description: Normal Saline
Study: NCT02813460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation G2 (ALS-008176)
Description: 60 mg/mL ALS-008176 oral suspension with concentration 2 of sucralose (maximum 12 mg/mL) and best flavor 1 from session 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation G2 (ALS-008176)
Description: 60 mg/mL ALS-008176 oral suspension with concentration 2 of sucralose (maximum 12 mg/mL) and best flavor 1 from session 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation G2 (ALS-008176)
Description: 60 mg/mL ALS-008176 oral suspension with concentration 2 of sucralose (maximum 12 mg/mL) and best flavor 1 from session 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation G2 (ALS-008176)
Description: 60 mg/mL ALS-008176 oral suspension with concentration 2 of sucralose (maximum 12 mg/mL) and best flavor 1 from session 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation G2 (ALS-008176)
Description: 60 mg/mL ALS-008176 oral suspension with concentration 2 of sucralose (maximum 12 mg/mL) and best flavor 1 from session 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation G3 (ALS-008176)
Description: 60 mg/mL ALS-008176 oral suspension with concentration 3 of sucralose (maximum 12 mg/mL) and best flavor 1 from session 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation G3 (ALS-008176)
Description: 60 mg/mL ALS-008176 oral suspension with concentration 3 of sucralose (maximum 12 mg/mL) and best flavor 1 from session 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation G3 (ALS-008176)
Description: 60 mg/mL ALS-008176 oral suspension with concentration 3 of sucralose (maximum 12 mg/mL) and best flavor 1 from session 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation G3 (ALS-008176)
Description: 60 mg/mL ALS-008176 oral suspension with concentration 3 of sucralose (maximum 12 mg/mL) and best flavor 1 from session 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation G3 (ALS-008176)
Description: 60 mg/mL ALS-008176 oral suspension with concentration 3 of sucralose (maximum 12 mg/mL) and best flavor 1 from session 1.
Study: NCT03025412

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endoscopic surgery
Description: Ambulatory surgery. Same surgeon for all patients. General anesthesia. Full debridement of the paratenon and crural fascia. Also the plantaris longus tendon is debrided, but no additional tenotomy executed. Postoperative rehabilitation. Oral nonsteroidal anti-inflammatory drugs 7 days postoperatively. Active ankle dorsiflexion and plantar flexion from day 1 postoperative. Partly weight bearing (30 kg) from day 1 postoperative. Full weight bearing allowed from week 3 postoperative. Gradually increased load, both in activity of daily living, stationary bike and stretching, with individually and pragmatic progression due to pain response. From week 6 postoperative the patients start the same exercise regimen as the conservative treatment group.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: physiotherapy and exercise
Description: Exercise schedule: Weeks 1-6, Eccentric unilateral loading while standing on the step of a staircase performed in two exercises; with straight knee and with bent knee. Weeks 7-9, Eccentric - Concentric loading while standing on the step of a staircase performed with straight knee and bent knee. Dose: 15 repetitions x 3 performed with straight knee, and 15 repetitions x 3 performed with bent knee. 3 - 4 times a week. Weeks 10-12, Eccentric - Concentric loading while standing on the step of a staircase performed with straight knee and bent knee. Dose: 15 repetitions maximum (15RM) x 3 performed with straight knee, and 15 RM x 3 performed with bent knee. 3 - 4 times a week. One leg performance or hand hold weight for extra load is used to obtain the exact number of RM.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physiotherapy and exercise
Description: Exercise schedule: Weeks 1-6, Eccentric unilateral loading while standing on the step of a staircase performed in two exercises; with straight knee and with bent knee. Weeks 7-9, Eccentric - Concentric loading while standing on the step of a staircase performed with straight knee and bent knee. Dose: 15 repetitions x 3 performed with straight knee, and 15 repetitions x 3 performed with bent knee. 3 - 4 times a week. Weeks 10-12, Eccentric - Concentric loading while standing on the step of a staircase performed with straight knee and bent knee. Dose: 15 repetitions maximum (15RM) x 3 performed with straight knee, and 15 RM x 3 performed with bent knee. 3 - 4 times a week. One leg performance or hand hold weight for extra load is used to obtain the exact number of RM.
Study: NCT02010203

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HS-410
Description: Vaccine derived from irradiated cancer cells genetically engineered to continually secrete gp96

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HS-410
Description: Vaccine derived from irradiated cancer cells genetically engineered to continually secrete gp96

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HS-410
Description: Vaccine derived from irradiated cancer cells genetically engineered to continually secrete gp96

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HS-410
Description: Vaccine derived from irradiated cancer cells genetically engineered to continually secrete gp96

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injection containing sterile solution but no cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG
Description: Vaccine derived from a live bacterium

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG
Description: Vaccine derived from a live bacterium

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: BCG
Description: Vaccine derived from a live bacterium
Study: NCT01202422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin controlled release, 165 mg
Description: Two tablets of 165 mg controlled release (administered concurrently) once daily for four days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin controlled release, 330 mg
Description: 330 mg controlled release tablet administered once daily for four days.

Intervention type: DRUG
Group type: OTHER
Intervention: Pregabalin immediate release, 150 mg
Description: 150 mg immediate release capsules administered every 12 hours for four days
Study: NCT03382925

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cervical interlaminar with lidocaine
Description: Interlaminar cervical epidural steroid injection at the C7-T1 level with triamcinolone 80 mg (40 mg/mL) + 2 mL 1% lidocaine.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cervical interlaminar with normal saline
Description: Interlaminar cervical epidural steroid injection at the C7-T1 level with triamcinolone 80 mg (40 mg/mL) + 2 mL preservative saline
Study: NCT02832999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sub cutaneous liraglutide
Description: Liraglutide 1.2mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Vildagliptin
Description: Vildagliptin 50mg/day
Study: NCT02595749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT01047501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMR101 (ethyl icosapentate) - 4 g/day
Description: AMR101 (ethyl icosapentate) 4 capsules/day for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMR101 (ethyl icosapentate) - 2 g/day
Description: AMR101 (ethyl icosapentate) 2 capsules/day with placebo 2 capsules/day for 12 weeks
Study: NCT00811629

Intervention type: OTHER
Intervention: sRAGE
Description: The purpose of this observational prospective study is to determine wether sRAGE could be used in an ICU setting as a potential diagnostic and prognostic marker during ALI/ARDS, regardless of associated severe sepsis or septic shock
Study: NCT01047501

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 4 capsules/day for 12 weeks
Study: NCT00689832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus 0.03%
Description: ointment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone 0.005%
Description: ointment
Study: NCT03415256

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: passive vibration
Description: The passive vibration is delivered using a Physio Plate (Domino S.R.L, San Vendemiano, Italy). The frequency delivered is 50 Hz for a total number of ten cycles for a period of ten minutes approximately (one cycle= 60seconds working time with 2 seconds rest time).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: no passive vibration
Description: The control group will not receive any treatment and continue their usual lifestyle.
Study: NCT00005988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: in vitro-treated bone marrow transplantation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT00592293

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Beam Radiation
Description: Once per day, 5 days a week for a total of 4 to 6 weeks.
Study: NCT02072044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib p.o. qd
Study: NCT03406468

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Patients continue the same immune therapy they already received and get radiotherapy to one lesion. The lesion may or may not be symptomatic. The preferred radiotherapy dose is 24 Gy in 3 fractions (dosage on the 10 Gy isodose is allowed), but other fractionation schedules (e.g. 30 Gy/ 10 fractions, 20 Gy/ 5 fractions, 20-24 Gy / 1 fraction for SRS (stereotactic radiosurgery)) are allowed if these are standard for a certain location or palliative indication in the body.
Study: NCT02049762

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin 100 mg vs. placebo in ACS patients on P2Y12 inhibitors a month following PCI.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin
Description: Aspirin 100 mg vs. placebo in ACS patients on P2Y12 inhibitors a month following PCI.
Study: NCT00741611

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HD Mesh Ablation System
Description: Ablation using the HD Mesh Ablation System

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-arrhythmic drugs
Description: 5 anti-arrhythmic drugs administered at the labeled dosage for atrial fibrillation
Study: NCT04424901

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily dose while hospitalized up to 9 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dipyridamole Tablets
Description: Daily dose while hospitalized up to 9 days
Study: NCT01286324

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chamomile High Grade Extract
Description: three tablets each (equivalent to 7.5 g of dried herb) p.o. twice daily for 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tablet
Study: NCT02813460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation G3 (ALS-008176)
Description: 60 mg/mL ALS-008176 oral suspension with concentration 3 of sucralose (maximum 12 mg/mL) and best flavor 1 from session 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation H1 (ALS-008176)
Description: 60 mg/mL ALS-008176 oral suspension with concentration 1 of sucralose (maximum 12 mg/mL) and best flavor 2 from session 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation H1 (ALS-008176)
Description: 60 mg/mL ALS-008176 oral suspension with concentration 1 of sucralose (maximum 12 mg/mL) and best flavor 2 from session 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation H1 (ALS-008176)
Description: 60 mg/mL ALS-008176 oral suspension with concentration 1 of sucralose (maximum 12 mg/mL) and best flavor 2 from session 1.
Study: NCT01413269

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiotherapy
Description: one group receives radiation to the whole breast to a total dose of 43.5Gy,at 2.9Gy per fraction, 5 fractions a week, followed by tumor bed boost of 8.7Gy, at 2.9Gy per fraction 5 fractions a week.~the other group receives radiation to the whole breast to a total dose of 50Gy,at 2.0Gy per fraction, 5 fractions a week, followed by tumor bed boost of 10Gy, at 2.0Gy per fraction 5 fractions a week.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: one group receives radiation to the whole breast to a total dose of 43.5Gy,at 2.9Gy per fraction, 5 fractions a week, followed by tumor bed boost of 8.7Gy, at 2.9Gy per fraction 5 fractions a week.~the other group receives radiation to the whole breast to a total dose of 50Gy,at 2.0Gy per fraction, 5 fractions a week, followed by tumor bed boost of 10Gy, at 2.0Gy per fraction 5 fractions a week.
Study: NCT00351715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sublingual Methadone
Study: NCT01014715

Intervention type: OTHER
Group type: OTHER
Intervention: Phase II - Preoperative Radiation followed by Lumpectomy.
Description: Sequential investigative question. All procedures are standard of care